Effects of rearrangement and allelic exclusion of JJAZ1/SUZ12 on cell proliferation and survival

Polycomb group genes (PcGs) have been implicated in cancer based on altered levels of expression observed in certain tumors and the behavior of cultured cells containing inserted PcG transgenes. Endometrial stromal tumors provide evidence for a direct causal relationship because they contain several chromosomal translocations and resultant gene fusions involving PcGs, the most common of which joins portions of theJAZF1 gene to the PcGJJAZ1/SUZ12. We show here that both benign and malignant forms of this tumor have theJAZF1–JJAZ1 fusion but only the malignant form also exhibits exclusion of the unrearrangedJJAZ1 allele. To evaluate the effects of both theJJAZ1/SUZ12 fusion and allelic exclusion on functions related to cell growth, we studied HEK293 cells that were modified with respect toJJAZ1 expression. We found that theJAZF1–JJAZ1 fusion restored levels of the polycomb protein EZH2 and histone 3 lysine 27 trimethylation, which were reduced by knockdown of endogenous JJAZ1. At the same time, the presence ofJAZF1–JJAZ1 markedly inhibited apoptosis and induced above normal proliferation rates, although the latter effect occurred only when normalJJAZ1 was suppressed. Our findings suggest a genetic pathway for progression of a benign precursor to a sarcoma involving increased cell survival associated with acquisition of a PcG rearrangement, followed by accelerated cellular proliferation upon allelic exclusion of the unrearranged copy of that gene. Furthermore, these results indicate the likely functional importance of allelic exclusion of genes disrupted by chromosomal translocations, as seen in a variety of other cancers.

[1]  C. Scher,et al.  Direct transformation of 3T3 cells by Abelson murine leukaemia virus , 1975, Nature.

[2]  M. Wigler,et al.  Human-tumor-derived cell lines contain common and different transforming genes , 1981, Cell.

[3]  Robert A. Weinberg,et al.  Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes , 1983, Nature.

[4]  T. Littlewood,et al.  Chromatin structure of transcriptionally active and inactive human c‐myc alleles. , 1985, The EMBO journal.

[5]  J. Sklar,et al.  Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation , 1986, Cell.

[6]  Unnamed Blaustein's Pathology of the Female Genital Tract , 2019, Springer International Publishing.

[7]  E. Freed,et al.  Transformation of NIH 3T3 cells by cotransfection with c-src and nuclear oncogenes , 1987, Molecular and cellular biology.

[8]  D. Eick,et al.  Expression of normal and translocated c‐myc alleles in Burkitt's lymphoma cells: evidence for different regulation. , 1989, The EMBO journal.

[9]  K. Chang,et al.  Primary Uterine Endometrial Stromal Neoplasms: A Clinicopathologic Study of 117 Cases , 1990, The American journal of surgical pathology.

[10]  H. van den Berghe,et al.  Endometrial stromal sarcoma t(7;17)(p15-21;q12-21) is a nonrandom chromosome change. , 1992, Cancer genetics and cytogenetics.

[11]  Y. Haupt,et al.  bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis. , 1993, Oncogene.

[12]  Gertrude S. Crabtree,et al.  Primary extrauterine endometrial stromal neoplasms: a clinicopathologic study of 20 cases and a review of the literature. , 1993, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[13]  I. Simon,et al.  Allelic inactivation regulates olfactory receptor gene expression , 1994, Cell.

[14]  T. Rollason Blaustein’s Pathology of the Female Genital Tract , 2003, Springer New York.

[15]  P. Glazer,et al.  Genetic instability induced by the tumor microenvironment. , 1996, Cancer research.

[16]  R. Sciot,et al.  Cytogenetics revealing the diagnosis in a metastatic endometrial stromal sarcoma. , 1996, Histopathology.

[17]  J. Bullerdiek,et al.  A third case of a low-grade endometrial stromal sarcoma with a t(7;17)(p14∼21;q11.2∼21) , 1997 .

[18]  C Terhorst,et al.  Monoallelic expression of the interleukin-2 locus. , 1998, Science.

[19]  S. Krichevsky,et al.  ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. , 1999, Blood.

[20]  C. Allis,et al.  The language of covalent histone modifications , 2000, Nature.

[21]  Hitoshi Sakano,et al.  Mutually exclusive expression of odorant receptor transgenes , 2000, Nature Neuroscience.

[22]  E. Campo,et al.  BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. , 2001, Cancer research.

[23]  A. Birve,et al.  Su(z)12, a novel Drosophila Polycomb group gene that is conserved in vertebrates and plants. , 2001, Development.

[24]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[25]  J. Sklar,et al.  Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  V. Pirrotta,et al.  Drosophila Enhancer of Zeste/ESC Complexes Have a Histone H3 Methyltransferase Activity that Marks Chromosomal Polycomb Sites , 2002, Cell.

[27]  Brigitte Wild,et al.  Histone Methyltransferase Activity of a Drosophila Polycomb Group Repressor Complex , 2002, Cell.

[28]  D. Reinberg,et al.  Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. , 2002, Genes & development.

[29]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[30]  Hengbin Wang,et al.  Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing , 2002, Science.

[31]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Yi Zhang,et al.  The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. , 2004, Current opinion in genetics & development.

[33]  A. Lund,et al.  Polycomb complexes and silencing mechanisms. , 2004, Current opinion in cell biology.

[34]  Yi Zhang,et al.  SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. , 2004, Molecular cell.

[35]  Stuart S Levine,et al.  Division of labor in polycomb group repression. , 2004, Trends in biochemical sciences.

[36]  Yong-Sik Kim,et al.  TIP27: a novel repressor of the nuclear orphan receptor TAK1/TR4. , 2004, Nucleic acids research.

[37]  Kristian Helin,et al.  Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity , 2004, The EMBO journal.

[38]  A. Rosenwald,et al.  Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  S. Gibson,et al.  Hypoxia-induced phosphorylation of Chk2 in an ataxia telangiectasia mutated-dependent manner. , 2005, Cancer research.

[40]  J. Aster,et al.  c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. , 2006, Genes & development.

[41]  Anke Sparmann,et al.  Polycomb silencers control cell fate, development and cancer , 2006, Nature Reviews Cancer.

[42]  Vincenzo Pirrotta,et al.  Polycomb silencing mechanisms and the management of genomic programmes , 2007, Nature Reviews Genetics.

[43]  J. Sklar,et al.  Molecular Analysis of the JAZF1-JJAZ1 Gene Fusion by RT-PCR and Fluorescence In Situ Hybridization in Endometrial Stromal Neoplasms , 2007, The American journal of surgical pathology.